These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 32446385)
1. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC. Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385 [TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326 [TBL] [Abstract][Full Text] [Related]
3. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer. Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010 [TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992 [TBL] [Abstract][Full Text] [Related]
6. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition. Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374 [TBL] [Abstract][Full Text] [Related]
7. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer. Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179 [TBL] [Abstract][Full Text] [Related]
8. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575 [TBL] [Abstract][Full Text] [Related]
9. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075 [TBL] [Abstract][Full Text] [Related]
10. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535 [TBL] [Abstract][Full Text] [Related]
12. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722 [TBL] [Abstract][Full Text] [Related]
19. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040 [TBL] [Abstract][Full Text] [Related]
20. mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer. Chiang CT; Demetriou AN; Ung N; Choudhury N; Ghaffarian K; Ruderman DL; Mumenthaler SM Cancer Lett; 2018 Oct; 434():152-159. PubMed ID: 30036610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]